- Home
- GMM vs CHRS Comparison
GMM vs CHRS Comparison
Compare GMM & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- CHRS
- Stock Information
- Founded
- GMM 2017
- CHRS 2010
- Country
- GMM China
- CHRS United States
- Employees
- GMM N/A
- CHRS N/A
- Industry
- GMM
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMM
- CHRS Health Care
- Exchange
- GMM Nasdaq
- CHRS Nasdaq
- Market Cap
- GMM 70.8M
- CHRS 84.2M
- IPO Year
- GMM 2023
- CHRS 2014
- Fundamental
- Price
- GMM $2.54
- CHRS $0.73
- Analyst Decision
- GMM
- CHRS Buy
- Analyst Count
- GMM 0
- CHRS 3
- Target Price
- GMM N/A
- CHRS $4.68
- AVG Volume (30 Days)
- GMM 14.3K
- CHRS 1.3M
- Earning Date
- GMM 07-11-2025
- CHRS 08-07-2025
- Dividend Yield
- GMM N/A
- CHRS N/A
- EPS Growth
- GMM 62.17
- CHRS N/A
- EPS
- GMM 6.37
- CHRS N/A
- Revenue
- GMM $41,360,953.00
- CHRS $272,251,000.00
- Revenue This Year
- GMM N/A
- CHRS N/A
- Revenue Next Year
- GMM N/A
- CHRS $106.56
- P/E Ratio
- GMM $0.40
- CHRS N/A
- Revenue Growth
- GMM 53.82
- CHRS 19.87
- 52 Week Low
- GMM $1.69
- CHRS $0.66
- 52 Week High
- GMM $15.60
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- GMM 40.95
- CHRS 41.45
- Support Level
- GMM $2.77
- CHRS $0.72
- Resistance Level
- GMM $2.73
- CHRS $0.77
- Average True Range (ATR)
- GMM 0.14
- CHRS 0.04
- MACD
- GMM -0.04
- CHRS 0.00
- Stochastic Oscillator
- GMM 14.40
- CHRS 13.65
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.